◎ Sugi Atlas

Atlas / Drug / Filgrastim

Filgrastim

drug
On this page

Also known as AccofilBiograstimEP-2006Ep2006Filgrastim aafiFilgrastim ayowFilgrastim for bioassayFilgrastim hexalFilgrastim ratiopharmFilgrastim sndzFilgrastim-aafiFilgrastim-sndzFSK-0808FSK0808Gran 300Gran injection 150GranixGrastofilKRN-8601

Summary

Filgrastim (CHEMBL1201567) is an approved protein (ATC L03AA02); indicated across 183 conditions including neoplasm and neutropenia.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Protein
  • ATC class: L03AA02
  • Indications: 183 conditions
  • Clinical trials: 880

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1201567
NameFilgrastim
TypeProtein
Max phase4
ATCL03AA02

Also known as: Accofil, Biograstim, EP-2006, Ep2006, Filgrastim, Filgrastim aafi, Filgrastim ayow, Filgrastim for bioassay, Filgrastim hexal, Filgrastim ratiopharm, Filgrastim sndz, Filgrastim-aafi

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

183 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
neoplasm4MONDO:0005070EFO:0000616
neutropenia4MONDO:0001475MONDO:0001475
cirrhosis of liver3MONDO:0005155EFO:0001422
leukemia3MONDO:0005059EFO:0000565
Chagas cardiomyopathy3MONDO:0005491EFO:0005529
acute myeloid leukemia3MONDO:0018874EFO:0000222
plasma cell myeloma3MONDO:0009693EFO:0001378
non-small cell lung carcinoma3MONDO:0005233EFO:0003060
myelodysplastic syndrome3MONDO:0018881EFO:0000198
lymphoma3MONDO:0005062EFO:0000574
sarcoma3MONDO:0005089EFO:0000691
acute lymphoblastic leukemia3MONDO:0004967EFO:0000220
neoplasm of mature B-cells3MONDO:0004949EFO:0000096
non-Hodgkin lymphoma3MONDO:0018908EFO:0005952
alcoholic hepatitis3MONDO:0001505EFO:1001345
B-cell chronic lymphocytic leukemia3MONDO:0004948EFO:0000095
Hodgkins lymphoma3MONDO:0004952EFO:0000183
acute monocytic leukemia3MONDO:0007896EFO:0000221
acute myelomonocytic leukemia M43MONDO:0018871EFO:0000223
Burkitt lymphoma3MONDO:0007243EFO:0000309
cutaneous melanoma3MONDO:0005012EFO:0000389
diffuse large B-cell lymphoma3MONDO:0018905EFO:0000403
germ cell tumor3MONDO:0005040EFO:0000514
myocardial infarction3MONDO:0005068EFO:0000612
neuroblastoma3MONDO:0005072EFO:0000621
systemic sclerosis3MONDO:0005100EFO:0000717
melanoma3MONDO:0005105EFO:0000756
liver disorder3MONDO:0005154EFO:0001421
rhabdomyosarcoma3MONDO:0005212EFO:0002918
medulloblastoma3MONDO:0007959EFO:0002939
acute megakaryoblastic leukemia3MONDO:0018872EFO:0003025
acute myeloblastic leukemia without maturation3MONDO:0005224EFO:0003027
acute basophilic leukemia3MONDO:0019458EFO:0003029
myelodysplastic syndrome with single lineage dysplasia3MONDO:0005272EFO:0003802
breast neoplasm3MONDO:0021100EFO:0003869
ovarian neoplasm3MONDO:0021068EFO:0003893
relapsing-remitting multiple sclerosis3MONDO:0005314EFO:0003929
primitive neuroectodermal tumor3MONDO:0005462EFO:0005235
triple-negative breast carcinoma3MONDO:0005494EFO:0005537
head and neck cancer3MONDO:0005627EFO:0006859
aplastic anemia3MONDO:0015909EFO:0006927
mantle cell lymphoma3MONDO:0018876EFO:1001469
brain neoplasm3MONDO:0021211EFO:0003833
adrenal cortex carcinoma3MONDO:0006639EFO:1000796
chronic myelomonocytic leukemia3MONDO:0020311EFO:1001779
liver failure3MONDO:0100192HP:0001399
T-cell acute lymphoblastic leukemia3MONDO:0004963EFO:0000209
acute erythroid leukemia3MONDO:0017858EFO:0000218
adrenal gland pheochromocytoma3MONDO:0004974EFO:0000239
myeloproliferative neoplasm3MONDO:0020076EFO:0002428
myelodysplastic syndrome with excess blasts3MONDO:0019454EFO:0003811
anemia3MONDO:0002280EFO:0004272
testicular cancer3MONDO:0005447EFO:0004281
mediastinal cancer3MONDO:0005843EFO:0007362
central nervous system neoplasm3MONDO:0006130EFO:1000158
soft tissue sarcoma3MONDO:0018078EFO:1001968
brain cancer3MONDO:0001657MONDO:0001657
kidney cancer3MONDO:0002367MONDO:0002367
ovarian cancer3MONDO:0008170MONDO:0008170
lung neoplasm3MONDO:0021117MONDO:0008903
endometrium neoplasm3MONDO:0021251MONDO:0011962
graft versus host disease3MONDO:0013730MONDO:0013730
follicular lymphoma3MONDO:0018906MONDO:0018906
acute biphenotypic leukemia3MONDO:0020322MONDO:0019460
primary ovarian failure3MONDO:0005387HP:0008209
B-cell acute lymphoblastic leukemia3MONDO:0004947EFO:0000094
acute myocardial infarction3MONDO:0004781EFO:0008583
retinoblastoma3MONDO:0008380MONDO:0008380
hereditary amyloidosis3MONDO:0018634MONDO:0019438
uterine corpus cancer3MONDO:0006003EFO:0007532
ST-elevation myocardial infarction3MONDO:0041656EFO:0008585
ependymoma3MONDO:0016698MONDO:0016700
plasma cell neoplasm3MONDO:0004959EFO:0000200
tumor of uterus3MONDO:0021353EFO:0003859
hematologic disorder2MONDO:0005570HP:0001871
infertility disorder2MONDO:0005047EFO:0000545
lymphoid neoplasm2MONDO:0005157EFO:0001642
head and neck squamous cell carcinoma2MONDO:0010150EFO:0000181
hepatocellular carcinoma2MONDO:0007256EFO:0000182
metastatic prostate carcinoma2MONDO:0004956EFO:0000196
peripheral T-cell lymphoma, not otherwise specified2MONDO:0004964EFO:0000211
chronic myeloid leukemia2MONDO:0011996EFO:0000339
Crohn disease2MONDO:0005011EFO:0000384
dilated cardiomyopathy2MONDO:0005021EFO:0000407
osteosarcoma2MONDO:0009807EFO:0000637
renal cell carcinoma2MONDO:0005086EFO:0000681
small cell lung carcinoma2MONDO:0008433EFO:0000702
stroke disorder2MONDO:0005098EFO:0000712
HIV infectious disease2MONDO:0005109EFO:0000764
exocrine pancreatic carcinoma2MONDO:0005192EFO:0002618
anaplastic large cell lymphoma2MONDO:0020325EFO:0003032
colorectal neoplasm2MONDO:0005335EFO:0004142
male breast carcinoma2MONDO:0005628EFO:0006861
mast cell leukemia2MONDO:0020334EFO:0007359
cerebral palsy2MONDO:0006497EFO:1000632
inflammatory breast carcinoma2MONDO:0006804EFO:1000984
gliosarcoma2MONDO:0016681EFO:1001465
epidermolysis bullosa dystrophica2MONDO:0006543Orphanet:303
Ewing sarcoma2MONDO:0012817EFO:0000174
neuromyelitis optica2MONDO:0019100EFO:0004256
Langerhans cell histiocytosis2MONDO:0018310EFO:1000318
carcinoma2MONDO:0004993EFO:0000313
pancreatic endocrine carcinoma2MONDO:0005893EFO:0007416
gastric neoplasm2MONDO:0021085MONDO:0001056
peritoneal neoplasm2MONDO:0006901MONDO:0002087
fallopian tube neoplasm2MONDO:0021092MONDO:0002158
myeloid leukemia2MONDO:0004643MONDO:0004643
T-cell non-Hodgkin lymphoma2MONDO:0015760MONDO:0015760
hematopoietic and lymphoid system neoplasm2MONDO:0002334MONDO:0044881
pemphigus2MONDO:0006594EFO:1000749
lymphopenia2MONDO:0003783MONDO:0003783
myelodysplastic/myeloproliferative disease2MONDO:0020077MONDO:0020077
amyotrophic lateral sclerosis2MONDO:0004976MONDO:0004976
type 1 diabetes mellitus2MONDO:0005147MONDO:0005147
Parkinson disease2MONDO:0005180MONDO:0005180
Wilms tumor2MONDO:0006058MONDO:0006058
biliary atresia2MONDO:0008867MONDO:0008867
sickle cell disease2MONDO:0011382MONDO:0011382
Fanconi anemia2MONDO:0019391MONDO:0019391
endometriosis2MONDO:0005133EFO:0001065
systemic lupus erythematosus2MONDO:0007915MONDO:0007915
glioblastoma2MONDO:0018177EFO:0000519
lung large cell carcinoma2MONDO:0003050EFO:0003050
gallbladder neoplasm2MONDO:0021253MONDO:0005411
Diamond-Blackfan anemia2MONDO:0015253MONDO:0015253
nasopharyngeal carcinoma2MONDO:0015459MONDO:0015459
carcinoid tumor2MONDO:0005369MONDO:0024503
peripheral arterial disease1MONDO:0005386EFO:0004265
acute promyelocytic leukemia1MONDO:0012883EFO:0000224
primary myelofibrosis1MONDO:0009692EFO:0002430
necrotizing enterocolitis1MONDO:0005313EFO:0003928
plasma cell leukemia1MONDO:0018689EFO:0006475
MALT lymphoma1MONDO:0007650EFO:0000191
endometrioid adenocarcinoma1MONDO:0005026EFO:0000466
malignant peripheral nerve sheath tumor1MONDO:0017827EFO:0000760
synovial sarcoma1MONDO:0010434EFO:0001376
myopathy1MONDO:0005336EFO:0004145
myasthenia gravis1MONDO:0009688EFO:0004991
vasculitis1MONDO:0018882EFO:0006803
stiff-person syndrome1MONDO:0008491EFO:0007498
Waldenstrom macroglobulinemia1MONDO:0100280EFO:0009441
ovarian serous cystadenocarcinoma1MONDO:0006046EFO:1000043
coronary artery disorder1MONDO:0005010EFO:0001645
blast phase chronic myelogenous leukemia, BCR-ABL1 positive1MONDO:0006115EFO:1000131
inborn error of immunity1MONDO:0003778HP:0002721
Alzheimer disease1MONDO:0004975MONDO:0004975
multiple sclerosis1MONDO:0005301MONDO:0005301
chordoma1MONDO:0008978MONDO:0008978
severe combined immunodeficiency1MONDO:0015974MONDO:0015974
beta thalassemia1MONDO:0019402Orphanet:848
ganglioneuroblastoma1MONDO:0005035EFO:0000502
angiosarcoma1MONDO:0016982EFO:0003968
central nervous system cancer1MONDO:0002714EFO:0000326
chronic granulomatous disease1MONDO:0018305MONDO:0018305
peripheral vascular disease0MONDO:0005294EFO:0003875

28 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 880.

Phase distribution

PhaseTrials
PHASE2408
PHASE1152
PHASE3142
PHASE1/PHASE2106
Not specified46
PHASE411
PHASE2/PHASE39
EARLY_PHASE16

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01553214PHASE4RECRUITINGImproving White Blood Cell Collection From Healthy Donors
NCT00003398PHASE4COMPLETEDBone Marrow Transplantation in Treating Patients With Hematologic Cancer
NCT00030758PHASE4UNKNOWNFilgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer
NCT01102699PHASE4COMPLETEDBone Marrow Progenitor Cell Mobilization in Diabetes
NCT01222819PHASE4TERMINATEDSubCutaneous (SC) Versus Intravenous (IV) Granulocyte Colony Stimulating Factors (G-CSF) for the Treatment of Neutropenia in Hospitalized Haemato-oncological Patients
NCT01859637PHASE4TERMINATEDImmunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia
NCT02408991PHASE4WITHDRAWNUse Art-assist and Neupogen to Treat Chronic Limb Ischemia
NCT02783937PHASE4COMPLETEDFilgrastim for Premature Ovarian Insufficiency
NCT02816112PHASE4COMPLETEDGranulocyte-colony Stimulating Factors or Antibiotics for Primary Prophylaxis for Febrile Neutropenia
NCT02816164PHASE4COMPLETEDA Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Febrile Neutropenia
NCT04781959PHASE4COMPLETEDA Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy
NCT00392327PHASE3ACTIVE_NOT_RECRUITINGChemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET
NCT00785525PHASE3RECRUITINGFilgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors
NCT02582697PHASE3RECRUITINGAccelerated v’s Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
NCT03007147PHASE3ACTIVE_NOT_RECRUITINGImatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT03907488PHASE3ACTIVE_NOT_RECRUITINGImmunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
NCT04651439PHASE2/PHASE3RECRUITINGSevere Bullous Drug Eruption and Filgrastim
NCT04759586PHASE3ACTIVE_NOT_RECRUITINGNivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
NCT05722015PHASE3ACTIVE_NOT_RECRUITINGA Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
NCT06188676PHASE3RECRUITINGMulticenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL
NCT06212752PHASE3ACTIVE_NOT_RECRUITINGA Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension
NCT00002539PHASE3COMPLETEDCombination Chemotherapy and Surgery With or Without G-CSF in Treating Patients With Osteosarcoma
NCT00002549PHASE3UNKNOWNCombination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia
NCT00002596PHASE3COMPLETEDCombination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors
NCT00002599PHASE3UNKNOWNCombination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma
NCT00002610PHASE3COMPLETEDChemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors
NCT00002611PHASE3COMPLETEDCombination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer
NCT00002618PHASE3COMPLETEDCombination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma
NCT00002641PHASE3COMPLETEDSurgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma
NCT00002649PHASE3COMPLETEDInterleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin’s Lymphoma
NCT00002658PHASE3UNKNOWNCombination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia
NCT00002719PHASE3COMPLETEDCombination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia
NCT00002755PHASE3COMPLETEDStandard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer
NCT00002757PHASE3COMPLETEDTITLE:Less Intensive Therapy for Children With Non-Hodgkin’s Lymphoma
NCT00002764PHASE3COMPLETEDSurgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma
NCT00002772PHASE3TERMINATEDS9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer
NCT00002784PHASE3COMPLETEDHigh-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer
NCT00002798PHASE3COMPLETEDCombination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
NCT00002827PHASE3COMPLETEDChemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin’s Disease
NCT00002835PHASE3COMPLETEDCombination Chemotherapy in Treating Patients With Lymphoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 15

This page pulls from 15 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclinical_trialsefogtopdb_interactiongtopdb_ligandmeshmondopatent_compoundpharmgkbpharmgkb_guidelinepubchem